TransMedics Group saw its IBD SmartSelect Composite Rating jump to 97 Friday, up from 94 the day before.
Lean How — And When — To Sell Stocks
The new rating is a sign the stock is outpacing 97% of all stocks when it comes to the most important stock-picking criteria. History shows the top market performers tend to have a 95 or higher score as they launch their major climbs.
TransMedics Group has now climbed above a proper buy zone after breaking out from a 92.63 buy point in a cup without handle.
One weak spot is the company's 79 EPS Rating, which tracks quarterly and annual earnings growth. Look for that to improve to 80 or better to show it's in the top 20% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
In Q1, the company reported 100% earnings growth. Top line growth came in at 48%, down from 50% in the prior quarter.
TransMedics Group holds the No. 3 rank among its peers in the Medical-Products industry group. Boston Scientific is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
